



GlaxoSmithKline


April 19, 2005

**GlaxoSmithKline**

PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709-3398

Tel. 919 483 2100  
www.gsk.com

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450" under 37 CFR 1.8(a) on April 19, 2005

  
Patty Wilson

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Re: United States Patent No. 6,861,441  
Issued: March 1, 2005  
Entitled *Use of EP4 Receptor Ligands in the Treatment of Neuropathic Pain and Colon Cancer*  
Serial No. 10/049,142  
Filed: August 8, 2000  
Attorney Docket No. PG3749USw

Sir:

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent, in accordance with 37 C.F.R. § 1.322. This request is made in order to correct the mistakes incurred through the fault of the Patent Office.

The error(s) as listed on the Certificate of Correction are references which were submitted to the U.S. Patent and Trademark Office on August 14, 2004 and considered by the Examiner on September 5, 2004. An additional copy of the Certificate of Correction is enclosed herewith, along with a return postcard in accordance with the present Patent Office practice.

Respectfully submitted,

  
Lorie Ann Morgan  
Registration No. 38,181

LAM/ptw  
Enclosures  
Customer No. 23347

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO : 6,861,441

DATED : March 1, 2005

INVENTOR(S) : Nicholas Maughan Clayton, Susanne Denise Collins, Steven Michael Foord, Gerard Martin Paul Giblin, Richard John Coles, Mark Bamford, Richard Green (deceased) by Jennifer M. Doughty

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

### (56) References Cited

#### FOREIGN PATENT DOCUMENTS

WO 99 /47497

WO 00/18405

WO 00/20371

WO 00/20398

#### OTHER PUBLICATIONS

Dumais, N., et al., "Prostaglandin E2 Up-Regulates HIV-1 Long Terminal Repeat-Driven Gene Activity in T Cells Via NF-kB-dependent and -independent Signaling Pathways" J. Biol. Chem., vol. 273, No. 42 pp. 27306-27314.

Rufer, C., et al. "New acylated 2-(4-aminophenyl)-propionicacids as anti-inflammatory agents" Eur J. Med. Chem-chim. Ther. 13(2)(1978) pp. 193-198.

MAILING ADDRESS OF SENDER: GlaxoSmithKline

Corporate Intellectual Property

Mai B475, Five Moore Drive

P. O. Box 13398

Research Triangle Park, NC 27709-3398

PATENT NO. 6,861,441

No. of additional copies



1

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO : 6,861,441

DATED : March 1, 2005

INVENTOR(S) : Nicholas Maughan Clayton, Susanne Denise Collins, Steven Michael Foord, Gerard Martin Paul Giblin, Richard John Coles, Mark Bamford, Richard Green (deceased) by Jennifer M. Doughty

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**(56) References Cited**

**FOREIGN PATENT DOCUMENTS**

WO 99 /47497

WO 00/18405

WO 00/20371

WO 00/20398

**OTHER PUBLICATIONS**

Dumais, N., et al., "Prostaglandin E2 Up-Regulates HIV-1 Long Terminal Repeat-Driven Gene Activity in T Cells Via NF-kB-dependent and -independent Signaling Pathways" J. Biol. Chem., vol. 273, No. 42 pp. 27306-27314.

Rufer, C., et al. "New acylated 2-(4-aminophenyl)-propionicacids as anti-inflammatory agents" Eur J. Med. Chem-chim. Ther. 13(2)(1978) pp. 193-198.

MAILING ADDRESS OF SENDER: GlaxoSmithKline

Corporate Intellectual Property  
Mai B475, Five Moore Drive  
P. O. Box 13398  
Research Triangle Park, NC 27709-3398

PATENT NO. 6,861,441

No. of additional copies



1